Echoing past contests and wars over gold and oil, governments are fighting for supremacy over minerals that could help countries achieve economic and technological dominance for decades to come
Some of the most fascinating topics covered this week are: Business (Importance of useless knowledge in business), Investing (Approaching investing amidst the second wave in India), Technology (The Big Tech battle over privacy), Mental Health (Laws of emotional mastery) and Sports (Effects of endurance exercise on the heart)
Five years ago Rajat Jaiswal co-founded the desi burger chain that now has 60 outlets across 21 cities. And he's steering clear of putting the business in auto-pilot mode
Globally, 41 percent of workers in the poorest 20 percent of their country's income distribution said they lost their job or business as a result of the pandemic, compared with 23 percent of workers in the richest 20 percent
The European Union is a significant force within the World Trade Organization, where unanimous approval by member countries would be required for any proposal to waive patents
With the recent amendments to CSR rules, a gruesome second coronavirus wave and reduced corporate performance due to the pandemic, social responsibility spend for companies is not going to be the same this fiscal
In a first in India, eight Asiatic lions have tested positive for the coronavirus. Here's what we know about the cause of Covid-19 infections in animals; limited experiments carried out in laboratories, and what the WHO recommends Covid-19 positive people
The humble oximeter has become a mainstay in every household amid the Covid-19 pandemic. A look at what the different readings mean, how they are calculated, and more
The Biden administration has come out in support of waiving intellectual property protections for coronavirus vaccines, siding with international efforts to bolster production amid concerns about vaccine access in developing nations
A small German company called CureVac is on the cusp of announcing the results of its late-stage clinical trial, and unlike the Moderna and Pfizer-BioNTech vaccine, the RNA vaccine made by CureVac doesn't need a deep freezer
A comprehensive understanding of the uptake barriers can help public health leaders and healthcare providers craft suitable communications and interventions to improve the overall testing figures